Abstract
Introduction: Syndecans are a family of cell surface proteoglycans. In the bone marrow of multiple myeloma patients syndecan-1 is expressed only on the surface of malignant plasma cells. The aim of the study was to determine the soluble syndecan-1 levels in different plasma cell dyscrasias. Methods: The serum concentration of soluble syndecan-1 was measured using human syndecan-1 enzyme-linked immunosorbent assay kit. Results: Patients with multiple myeloma showed a significantly higher median serum syndecan-1 level than patients with plasmocytoma or monoclonal gammopathy of undetermined significance. Statistically significant differences were also observed among Salmon-Durie subgroups of 50 patients suffering from multiple myeloma. In addition to these findings a statistical correlation with other independent prognostic factors such as serum beta2-microglobulin level, monoclonal immunoglobulin concentration, and bone marrow plasma cell count could also be noted. A significant decrease in median serum syndecan level was observed in patients who responded to chemotherapy, whereas no change in the median syndecan-1 level could be observed in nonresponders. Conclusion: These findings confirm the observation that high serum soluble syndecan-1 level is associated with a more advanced disease stage and is a strong independent indicator of poor prognosis. A diminished serum syndecan-1 reading as a result of chemotherapy may be a good indicator of favorable response to antitumor treatment.
| Original language | Hungarian |
|---|---|
| Pages (from-to) | 165-168 |
| Number of pages | 4 |
| Journal | Orvosi Hetilap |
| Volume | 146 |
| Issue number | 4 |
| Publication status | Published - 2005 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Szolúbilis syndecan-1- (CD 138)-koncentráció plazmasejt-dyscrasiákban. / Jánosi, Judit; Sebestyén, A.; Mikala, G.; Petö, Mónika; Jákó, János; Domján, Gyula; Németh, Júlia; Kis, Zoltán; Kópper, L.; Vályi-Nagy, István.
In: Orvosi Hetilap, Vol. 146, No. 4, 2005, p. 165-168.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Szolúbilis syndecan-1- (CD 138)-koncentráció plazmasejt-dyscrasiákban
AU - Jánosi, Judit
AU - Sebestyén, A.
AU - Mikala, G.
AU - Petö, Mónika
AU - Jákó, János
AU - Domján, Gyula
AU - Németh, Júlia
AU - Kis, Zoltán
AU - Kópper, L.
AU - Vályi-Nagy, István
PY - 2005
Y1 - 2005
N2 - Introduction: Syndecans are a family of cell surface proteoglycans. In the bone marrow of multiple myeloma patients syndecan-1 is expressed only on the surface of malignant plasma cells. The aim of the study was to determine the soluble syndecan-1 levels in different plasma cell dyscrasias. Methods: The serum concentration of soluble syndecan-1 was measured using human syndecan-1 enzyme-linked immunosorbent assay kit. Results: Patients with multiple myeloma showed a significantly higher median serum syndecan-1 level than patients with plasmocytoma or monoclonal gammopathy of undetermined significance. Statistically significant differences were also observed among Salmon-Durie subgroups of 50 patients suffering from multiple myeloma. In addition to these findings a statistical correlation with other independent prognostic factors such as serum beta2-microglobulin level, monoclonal immunoglobulin concentration, and bone marrow plasma cell count could also be noted. A significant decrease in median serum syndecan level was observed in patients who responded to chemotherapy, whereas no change in the median syndecan-1 level could be observed in nonresponders. Conclusion: These findings confirm the observation that high serum soluble syndecan-1 level is associated with a more advanced disease stage and is a strong independent indicator of poor prognosis. A diminished serum syndecan-1 reading as a result of chemotherapy may be a good indicator of favorable response to antitumor treatment.
AB - Introduction: Syndecans are a family of cell surface proteoglycans. In the bone marrow of multiple myeloma patients syndecan-1 is expressed only on the surface of malignant plasma cells. The aim of the study was to determine the soluble syndecan-1 levels in different plasma cell dyscrasias. Methods: The serum concentration of soluble syndecan-1 was measured using human syndecan-1 enzyme-linked immunosorbent assay kit. Results: Patients with multiple myeloma showed a significantly higher median serum syndecan-1 level than patients with plasmocytoma or monoclonal gammopathy of undetermined significance. Statistically significant differences were also observed among Salmon-Durie subgroups of 50 patients suffering from multiple myeloma. In addition to these findings a statistical correlation with other independent prognostic factors such as serum beta2-microglobulin level, monoclonal immunoglobulin concentration, and bone marrow plasma cell count could also be noted. A significant decrease in median serum syndecan level was observed in patients who responded to chemotherapy, whereas no change in the median syndecan-1 level could be observed in nonresponders. Conclusion: These findings confirm the observation that high serum soluble syndecan-1 level is associated with a more advanced disease stage and is a strong independent indicator of poor prognosis. A diminished serum syndecan-1 reading as a result of chemotherapy may be a good indicator of favorable response to antitumor treatment.
KW - Multiple myeloma
KW - Prognostic marker
KW - Syndecan-1
UR - http://www.scopus.com/inward/record.url?scp=15744388681&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=15744388681&partnerID=8YFLogxK
M3 - Article
C2 - 15751511
AN - SCOPUS:15744388681
VL - 146
SP - 165
EP - 168
JO - Orvosi Hetilap
JF - Orvosi Hetilap
SN - 0030-6002
IS - 4
ER -